Tiger BioSciences Spotlights Major Clinical and Scientific Milestones Following Significant 2025 Research Investment

CONSHOHOCKEN, Pa., Dec. 30, 2025 /PRNewswire/ -- Tiger BioSciences announced a collection of significant clinical and scientific accomplishments resulting from expanded research investments throughout 2025. The company reinforced its standing as a market frontrunner heading into 2026, with an increasingly data-driven and clinically validated product portfolio.

During 2025, the organization supported and produced five peer-reviewed retrospective clinical studies, with two concentrating on its primary offering, completeFT. These investigations underscore the product's effectiveness in sophisticated wound management and confirm its standing as a dependable resource for medical professionals nationwide.

The organization further demonstrated dedication to rigorous evidence by launching a prospective, randomized controlled trial assessing caregraFT's application for diabetic foot ulcers and venous leg ulcers. Preliminary results from this ongoing trial demonstrate encouraging clinical performance, highlighting caregraFT's promise as an emerging choice for persistent wound management.

"Meaningful clinical evidence forms the bedrock of enduring advancement in wound care. Our 2025 research commitments reflect our devotion to evidence-based medicine," stated Garrett Grinsfelder, President, Tiger Wound Care.

Going forward, Tiger BioSciences plans to broaden its clinical research initiatives with a randomized controlled trial examining caregraFT's performance in pressure ulcer management.

"With completed peer-reviewed studies and two active trials underway in 2026, Tiger is distinctly positioned as a market innovator with clinically validated products," added Grinsfelder.

About Tiger BioSciences

Tiger BioSciences operates as a vertically integrated cell and tissue technology enterprise engaged in recovery, processing, technology advancement, investigation, and commercialization of cellular, acellular, and matrix-based products. The organization functions simultaneously as a tissue recovery operation, processing innovator, and clinical partner dedicated to patients, providers, and donor families.

SOURCE Tiger BioSciences